- Published on
Emergency and Acute Medicine – Disseminated Intravascular Coagulation
Basics
Description
Normal coagulation consists of a localized series of reactions involving blood vessels, platelets, and clotting factors. Disseminated intravascular coagulation is a systemic activation of coagulation and fibrinolysis triggered by an underlying disease process. Widespread activation leads to circulation of thrombin and plasmin.
Thrombin activation occurs through tissue factor and factor VIIIa via the extrinsic pathway, resulting in fibrinogen conversion to fibrin monomers that polymerize into fibrin clots within the circulation. These clots cause microvascular and macrovascular thrombosis, leading to peripheral ischemia and end-organ damage. Platelets are consumed within clots, producing thrombocytopenia.
Plasmin activity results in degradation of fibrinogen into fibrin degradation products, which interfere with fibrin polymerization and impair platelet function, worsening bleeding.
Failure of physiologic anticoagulation is necessary for DIC to occur, with impairment of antithrombin III, the protein C system, and tissue factor pathway inhibitor.
Acute DIC represents an uncompensated state where clotting factors are consumed faster than they are replaced, making hemorrhage the dominant feature. Chronic DIC is a compensated state in which factor production keeps pace with consumption, and thrombosis predominates.
Etiology
DIC may be precipitated by numerous conditions. Obstetric causes include retained fetus, amniotic fluid embolism, placental abruption, abortion, eclampsia, and HELLP syndrome. Sepsis is a major trigger and may be caused by gram-negative bacteria through endotoxin, gram-positive organisms through mucopolysaccharides, or other microorganisms including viruses and parasites. Trauma-related causes include crush injury, severe burns, severe head injury, and fat embolism. Malignancy-associated DIC may occur with solid tumors, metastatic disease, or hematologic malignancies such as leukemia. Intravascular hemolysis from transfusion reactions or massive transfusion, organ destruction from severe pancreatitis or hepatic failure, vascular abnormalities such as Kasabach–Merritt syndrome or large aneurysms, and hematologic disorders such as thrombotic thrombocytopenic purpura or immune thrombocytopenic purpura may also precipitate DIC. Miscellaneous causes include snake envenomation and recreational drug use.
Diagnosis
Signs and symptoms
Bleeding manifestations include petechiae, purpura, hemorrhagic bullae, wound bleeding, oozing from venipuncture or arterial lines, epistaxis, hemoptysis, and gastrointestinal bleeding. Thrombotic manifestations include large-vessel thrombosis, microvascular thrombosis with end-organ dysfunction involving the heart, lungs, kidneys, liver, and central nervous system, thrombophlebitis, pulmonary embolism, nonbacterial thrombotic endocarditis, gangrene, and ischemic infarcts of the kidney, liver, bowel, or brain.
Acute DIC is characterized predominantly by hemorrhagic complications, whereas chronic DIC is dominated by thrombotic events.
History should assess prior bleeding disorders, pregnancy status, recent obstetric events, malignancy, and immunocompromised states.
Physical examination may reveal altered mental status, hypotension, tachycardia, tachypnea, pulmonary crackles, gastrointestinal bleeding, abdominal distension, oliguria, hematuria, petechiae, purpura, jaundice, or skin necrosis.
Essential workup
Evaluation depends on the precipitating illness. The diagnosis is often not definitively established in the emergency department and evolves with serial assessment.
Diagnosis tests and interpretation
Laboratory findings typically include a falling platelet count, often below 100,000/mm³, though it may be normal in chronic DIC. Prothrombin time and partial thromboplastin time are usually prolonged but may be normal in chronic disease. Fibrinogen levels are decreased in most acute cases but may remain normal, limiting sensitivity. Fibrin degradation products and D-dimer levels are elevated. Peripheral smear may show schistocytes and thrombocytopenia, particularly in chronic DIC. Renal dysfunction may be reflected by elevated BUN and creatinine, and arterial blood gases assess oxygenation and acid–base status.
The ISTH scoring system incorporates the presence of an underlying disorder, platelet count, fibrin markers, PT prolongation, and fibrinogen level. A score greater than five indicates overt DIC and is associated with increased mortality.
Imaging may include chest radiography for suspected pneumonia, head CT for altered mental status, and obstetric ultrasound in pregnant patients.
Differential diagnosis
Consider inherited factor deficiencies, anticoagulant or drug-induced coagulopathy, hepatic disease, vitamin K deficiency, massive blood loss, platelet dysfunction, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, heparin-induced thrombocytopenia, and immune thrombocytopenic purpura.
Treatment
Initial stabilization and therapy
Management focuses on airway protection, hemodynamic resuscitation, control of bleeding, intravenous access, and restoration of circulating volume. Prompt treatment of the underlying cause is essential, including antibiotics for sepsis, evacuation of retained products of conception, chemotherapy for malignancy, or surgical debridement for trauma.
Emergency department treatment and procedures
Specific therapy for DIC is controversial and should be individualized based on age, hemodynamic status, severity of bleeding, and degree of thrombosis. Early consultation with the admitting service is recommended.
Replacement of depleted blood components may include fresh frozen plasma for prolonged coagulation times, platelet transfusion for severe thrombocytopenia or active bleeding, and cryoprecipitate for severe hypofibrinogenemia. Recombinant factor VIIa has been reported in selected cases, though benefit and safety remain uncertain.
Heparin use is controversial and may be considered when thrombosis predominates, such as in purpura fulminans, acute promyelocytic leukemia, or chronic DIC with large-vessel thrombosis. Activated protein C and antithrombin supplementation have not demonstrated mortality benefit. Antifibrinolytic agents such as aminocaproic acid or tranexamic acid should be reserved for extreme cases with documented excessive fibrinolysis and refractory bleeding.
Medication
Definitive DIC-directed pharmacologic therapy is rarely initiated in the emergency department. Management emphasizes treatment of the underlying cause. Low-dose heparin infusion may be considered when thrombosis predominates.
Follow-up and disposition
Admission criteria
Patients with severe precipitating illness and DIC require intensive care unit admission.
Discharge criteria
There are no discharge criteria for patients with active DIC.
Follow-up recommendations
Ongoing management includes close monitoring of platelet counts, coagulation parameters, and organ function.
Pearls and pitfalls
DIC should be suspected as a complication of severe, life-threatening illness. Early recognition is critical, as the consequences can be catastrophic. Always address and treat the underlying cause, even when bleeding or thrombotic manifestations dominate the clinical presentation.
Basics
Description
Normal coagulation consists of a localized series of reactions involving blood vessels, platelets, and clotting factors. Disseminated intravascular coagulation is a systemic activation of coagulation and fibrinolysis triggered by an underlying disease process. Widespread activation leads to circulation of thrombin and plasmin.
Thrombin activation occurs through tissue factor and factor VIIIa via the extrinsic pathway, resulting in fibrinogen conversion to fibrin monomers that polymerize into fibrin clots within the circulation. These clots cause microvascular and macrovascular thrombosis, leading to peripheral ischemia and end-organ damage. Platelets are consumed within clots, producing thrombocytopenia.
Plasmin activity results in degradation of fibrinogen into fibrin degradation products, which interfere with fibrin polymerization and impair platelet function, worsening bleeding.
Failure of physiologic anticoagulation is necessary for DIC to occur, with impairment of antithrombin III, the protein C system, and tissue factor pathway inhibitor.
Acute DIC represents an uncompensated state where clotting factors are consumed faster than they are replaced, making hemorrhage the dominant feature. Chronic DIC is a compensated state in which factor production keeps pace with consumption, and thrombosis predominates.
Etiology
DIC may be precipitated by numerous conditions. Obstetric causes include retained fetus, amniotic fluid embolism, placental abruption, abortion, eclampsia, and HELLP syndrome. Sepsis is a major trigger and may be caused by gram-negative bacteria through endotoxin, gram-positive organisms through mucopolysaccharides, or other microorganisms including viruses and parasites. Trauma-related causes include crush injury, severe burns, severe head injury, and fat embolism. Malignancy-associated DIC may occur with solid tumors, metastatic disease, or hematologic malignancies such as leukemia. Intravascular hemolysis from transfusion reactions or massive transfusion, organ destruction from severe pancreatitis or hepatic failure, vascular abnormalities such as Kasabach–Merritt syndrome or large aneurysms, and hematologic disorders such as thrombotic thrombocytopenic purpura or immune thrombocytopenic purpura may also precipitate DIC. Miscellaneous causes include snake envenomation and recreational drug use.
Diagnosis
Signs and symptoms
Bleeding manifestations include petechiae, purpura, hemorrhagic bullae, wound bleeding, oozing from venipuncture or arterial lines, epistaxis, hemoptysis, and gastrointestinal bleeding. Thrombotic manifestations include large-vessel thrombosis, microvascular thrombosis with end-organ dysfunction involving the heart, lungs, kidneys, liver, and central nervous system, thrombophlebitis, pulmonary embolism, nonbacterial thrombotic endocarditis, gangrene, and ischemic infarcts of the kidney, liver, bowel, or brain.
Acute DIC is characterized predominantly by hemorrhagic complications, whereas chronic DIC is dominated by thrombotic events.
History should assess prior bleeding disorders, pregnancy status, recent obstetric events, malignancy, and immunocompromised states.
Physical examination may reveal altered mental status, hypotension, tachycardia, tachypnea, pulmonary crackles, gastrointestinal bleeding, abdominal distension, oliguria, hematuria, petechiae, purpura, jaundice, or skin necrosis.
Essential workup
Evaluation depends on the precipitating illness. The diagnosis is often not definitively established in the emergency department and evolves with serial assessment.
Diagnosis tests and interpretation
Laboratory findings typically include a falling platelet count, often below 100,000/mm³, though it may be normal in chronic DIC. Prothrombin time and partial thromboplastin time are usually prolonged but may be normal in chronic disease. Fibrinogen levels are decreased in most acute cases but may remain normal, limiting sensitivity. Fibrin degradation products and D-dimer levels are elevated. Peripheral smear may show schistocytes and thrombocytopenia, particularly in chronic DIC. Renal dysfunction may be reflected by elevated BUN and creatinine, and arterial blood gases assess oxygenation and acid–base status.
The ISTH scoring system incorporates the presence of an underlying disorder, platelet count, fibrin markers, PT prolongation, and fibrinogen level. A score greater than five indicates overt DIC and is associated with increased mortality.
Imaging may include chest radiography for suspected pneumonia, head CT for altered mental status, and obstetric ultrasound in pregnant patients.
Differential diagnosis
Consider inherited factor deficiencies, anticoagulant or drug-induced coagulopathy, hepatic disease, vitamin K deficiency, massive blood loss, platelet dysfunction, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, heparin-induced thrombocytopenia, and immune thrombocytopenic purpura.
Treatment
Initial stabilization and therapy
Management focuses on airway protection, hemodynamic resuscitation, control of bleeding, intravenous access, and restoration of circulating volume. Prompt treatment of the underlying cause is essential, including antibiotics for sepsis, evacuation of retained products of conception, chemotherapy for malignancy, or surgical debridement for trauma.
Emergency department treatment and procedures
Specific therapy for DIC is controversial and should be individualized based on age, hemodynamic status, severity of bleeding, and degree of thrombosis. Early consultation with the admitting service is recommended.
Replacement of depleted blood components may include fresh frozen plasma for prolonged coagulation times, platelet transfusion for severe thrombocytopenia or active bleeding, and cryoprecipitate for severe hypofibrinogenemia. Recombinant factor VIIa has been reported in selected cases, though benefit and safety remain uncertain.
Heparin use is controversial and may be considered when thrombosis predominates, such as in purpura fulminans, acute promyelocytic leukemia, or chronic DIC with large-vessel thrombosis. Activated protein C and antithrombin supplementation have not demonstrated mortality benefit. Antifibrinolytic agents such as aminocaproic acid or tranexamic acid should be reserved for extreme cases with documented excessive fibrinolysis and refractory bleeding.
Medication
Definitive DIC-directed pharmacologic therapy is rarely initiated in the emergency department. Management emphasizes treatment of the underlying cause. Low-dose heparin infusion may be considered when thrombosis predominates.
Follow-up and disposition
Admission criteria
Patients with severe precipitating illness and DIC require intensive care unit admission.
Discharge criteria
There are no discharge criteria for patients with active DIC.
Follow-up recommendations
Ongoing management includes close monitoring of platelet counts, coagulation parameters, and organ function.
Pearls and pitfalls
DIC should be suspected as a complication of severe, life-threatening illness. Early recognition is critical, as the consequences can be catastrophic. Always address and treat the underlying cause, even when bleeding or thrombotic manifestations dominate the clinical presentation.
0 Comments
